We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Immunoassay Evaluated for Detection of Helicobacter pylori

By LabMedica International staff writers
Posted on 02 Aug 2011
The efficacy of a new polyclonal enzyme immunoassay (EIA) for the detection of Helicobacter pylori antigen in feces has been determined. More...


The immunoassay has been compared with histology, rapid urease test, carbon-13 (13C)-urea breath test, and serology to determine the optimal cut-off value for screening a population at risk.

Scientists at Seoul National University (Seoul, Korea) prospectively enrolled 515 patients undergoing a routine health check-up. H. pylori infection was defined if at least two of four of the following tests: histology, rapid urease test, 13C-urea breath test, and serology, were positive. Stool samples were analyzed using a new polyclonal EIA stool antigen test, the EZ-STEP H. pylori, which was performed by the capture of polyclonal antibodies to H. pylori absorbed in microwells. The optimal cut-off value was determined by the receiver–operator characteristic curve. The diagnostic performance of each test was evaluated with regard to the histological diagnosis of atrophic gastritis (AG)/intestinal metaplasia (IM), degree of AG/IM, and old age.

The EZ-STEP H. pylori stool antigen test (Dinona Inc., Seoul, Korea) had a sensitivity of 93.1%, and specificity of 94.6% and was accurate 93.8% of the time. The sensitivity of histology, rapid urease test, and the 13C-urea breath test ranged from 89.1% to 97.6%, and their specificity was greater than 98%. The serological test, an enzyme-linked immunosorbent assay, identified as the H. pylori IgG EIA Well (Radim diagnostics, Rome, Italy) had high sensitivity, but low specificity. The stool antigen test still showed good diagnostic performance in the setting of progression of AG/IM and in patients over 40 years.

The authors concluded that the diagnostic performance of the new polyclonal stool antigen EIA was comparable to that of other methods used in the diagnosis of H. pylori infection in the screening population if an optimal cut-off value was determined. The stool antigen test might still be effective for the detection of H. pylori in the clinical settings of AG and/or IM and elderly patients. The study was published in June 2011, in the Journal of Gastroenterology and Hepatology.

Related Links:
Seoul National University
Radim diagnostics



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Laboratory Software
ArtelWare
New
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A simple blood sample that allows DNA methylation could identify epigenetic biomarkers (Photo courtesy of 123RF)

Simple Blood Sample Could Identify Epigenetic Biomarkers to Predict CVD Risk in Type 2 Diabetes

People with type 2 diabetes face up to four times higher risk of cardiovascular events such as heart attacks, strokes, and angina compared to individuals without the condition. Yet, current tools used... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The new technology could predict who will benefit from immunotherapy (Photo courtesy of Max Delbrück Center)

New Technology Deciphers Immune Cell Communication to Predict Immunotherapy Response

A healthy immune system depends on complex communication between specialized cell types that detect, alert, and eliminate harmful threats. When these immune signaling pathways break down, the result can... Read more

Industry

view channel
Image: The acquisition of Exosome Diagnostics adds the ExoDx Prostate test to Mdxhealth’s portfolio (Photo courtesy of Bio-Techne)

Bio-Techne Divests Exosome Diagnostics to Reposition Product Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has entered into an agreement with Mdxhealth SA (Irvine, CA, USA), which will acquire its Exosome Diagnostics Inc. (Waltham, MA, US) business, including the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.